A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Recruiting

Phase 1

KTX-2001 & DarolutamideA Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Sponsor:

K36 Therapeutics, Inc.

Code:

NCT07103018

Conditions

Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer Patients

Metastatic Castration-resistant Prostate Cancer, mCRPC

mCRPC

mCRPC (Metastatic Castration-resistant Prostate Cancer)

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KTX-2001

KTX-2001 + Darolutamide (NUBEQA®)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-14. This information was provided to ClinicalTrials.gov by K36 Therapeutics, Inc. on 2025-10-09.